In individuals with relapsed/refractory CHL, PD-1 inhibitors are an effective therapy strategy since 9p24.1 rearrangements in CHL are associated with PD-L1 overexpression on tumor cells in virtually all cases [41,42]. Here, CD274 is linked to neoplasm.